AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11096234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hormonal deprivation
Number of subjects: 43
Study 11096234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent androgen suppression
Number of subjects: 43
Study 9042671 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff-uroflow (CUF) technique
Number of subjects: 26
Study 9042671 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 26
Study 9042671 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 26
Study 8354733 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 or 100 mg)
Number of subjects: 0
Study 8354733 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 or 100 mg) + Ethanol (0.8 g/kg)
Number of subjects: 0
Study 3564877 — intervention group
Group type: COMPARATOR
Intervention: Bain system at VF of 125 ml X min‐1 X kg‐1 b.w.
Number of subjects: 34
Study 3564877 — intervention group
Group type: COMPARATOR
Intervention: Bain system at VF of 100 ml X min‐1 X kg‐1 b.w.
Number of subjects: 34
Study 3564877 — intervention group
Group type: COMPARATOR
Intervention: Lack system at VF of 70 ml X min‐1 X kg‐1 b.w.
Number of subjects: 34
Study 3564877 — intervention group
Group type: COMPARATOR
Intervention: Lack system at VF of 55 ml X min‐1 X kg‐1 b.w.
Number of subjects: 34
Study 30513923 — intervention group
Group type: EXPERIMENTAL
Intervention: CPO (composite supplement containing collagen peptide and ornithine)
Number of subjects: 22
Study 30513923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 27427811 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting-focused program for divorced families
Number of subjects: 240
Study 27427811 — intervention group
Group type: COMPARATOR
Intervention: Literature control condition
Number of subjects: 240
Study 25026889 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized invitation letter
Number of subjects: 4775
Study 25026889 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized invitation letter + informative leaflet
Number of subjects: 4775
Study 25026889 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized invitation letter + informative leaflet + personalized appointment reminder phone call
Number of subjects: 4775
Study 25026889 — intervention group
Group type: COMPARATOR
Intervention: No specific action taken (control group)
Number of subjects: 4775
Study 23113437 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Patient Simulator (HPS)
Number of subjects: 0
Study 23113437 — intervention group
Group type: COMPARATOR
Intervention: CD-ROM
Number of subjects: 0
Study 23113437 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 20202953 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of oral indomethacin
Number of subjects: 1
Study 20202953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 18722198 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational soccer (n = 14)
Number of subjects: 22
Study 18722198 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (n = 8)
Number of subjects: 22
Study 18722198 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention
Number of subjects: 22
Study 15910111 — intervention group
Group type: EXPERIMENTAL
Intervention: Active retinal tracker
Number of subjects: 2
Study 14959469 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril for a month
Number of subjects: 55
Study 14959469 — intervention group
Group type: COMPARATOR
Intervention: Adelphan and papasol for a month (Control)
Number of subjects: 55
Study 10703539 — intervention group
Group type: EXPERIMENTAL
Intervention: GADA (glutamic acid decarboxylase antibodies)
Number of subjects: 614
Study 10703539 — intervention group
Group type: EXPERIMENTAL
Intervention: ICA (islet cell antibodies)
Number of subjects: 614
Study 10703539 — intervention group
Group type: EXPERIMENTAL
Intervention: Double positivity for GADA and ICA
Number of subjects: 614
Study 10703539 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of ICA-positive children
Number of subjects: 614
Study 10703539 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of GADA-positive children
Number of subjects: 614
Study 8697549 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium continuous infusion starting at 0.6 mg.kg‐1.hr‐1, adjusted by 0.1 mg.kg‐1.hr‐1 to maintain one visible twitch of the TOF.
Number of subjects: 20
Study 1757603 — intervention group
Group type: EXPERIMENTAL
Intervention: Halobetasol propionate
Number of subjects: 0
Study 1757603 — intervention group
Group type: COMPARATOR
Intervention: Halobetasol propionate ointment
Number of subjects: 0
Study 6761135 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutron radiotherapy
Number of subjects: 0
Study 6761135 — intervention group
Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 0
Study 6761135 — intervention group
Group type: COMPARATOR
Intervention: Normal population
Number of subjects: 0
Study 31018892 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 684
Study 31018892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 684
Study 28094434 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil plus propofol
Number of subjects: 88
Study 28094434 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 88
Study 25758155 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT + CACR
Number of subjects: 57
Study 25758155 — intervention group
Group type: COMPARATOR
Intervention: CACR + control group
Number of subjects: 57
Study 23528398 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% emoxipine solution
Number of subjects: 0
Study 23528398 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% reamberin solution
Number of subjects: 0
Study 23528398 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% mexidol solution
Number of subjects: 0
Study 23528398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21647846 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of EMLA (2.5% lidocaine and 2.5% prilocaine)
Number of subjects: 60
Study 21647846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18796000 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg/IV within the first 2 weeks and at 3 months after transplantation
Number of subjects: 79
Study 18796000 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose infusions at the same time points)
Number of subjects: 79
Study 18796000 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg/IV
Number of subjects: 79
Study 18796000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 16774715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 0
Study 16774715 — intervention group
Group type: COMPARATOR
Intervention: Befriending (Control in LN study)
Number of subjects: 0
Study 16774715 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (Control in IS study)
Number of subjects: 0
Study 14992899 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic protective solution
Number of subjects: 64
Study 14992899 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 11698275 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/kg rabbit ATG (Thymoglobulin)
Number of subjects: 109
Study 11698275 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg rabbit ATG
Number of subjects: 109
Study 11698275 — intervention group
Group type: COMPARATOR
Intervention: No ATG
Number of subjects: 109
Study 11698275 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG
Number of subjects: 109
Study 9293721 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T Hib conjugate vaccine
Number of subjects: 42848
Study 9293721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42848
Study 8282480 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant interferon-alpha (rIFN-alpha) at a dose of 3 x 10(6) units thrice weekly for three months, followed by 1.5 x 10(6) units thrice weekly for the next three months
Number of subjects: 21
Study 8282480 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant interferon-alpha (rIFN-alpha)
Number of subjects: 21
Study 8282480 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 21
Study 2954221 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners
Number of subjects: 0
Study 2954221 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopaedists
Number of subjects: 0
Study 2954221 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractors
Number of subjects: 0
Study 2954221 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic subgroups
Number of subjects: 0
Study 29043861 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic nasobiliary drainage (ENBD)
Number of subjects: 160
Study 29043861 — intervention group
Group type: COMPARATOR
Intervention: No endoscopic nasobiliary drainage (no-ENBD)
Number of subjects: 160
Study 27843803 — intervention group
Group type: EXPERIMENTAL
Intervention: Duligotuzumab (1100 mg IV, q2w)
Number of subjects: 121
Study 27843803 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab (400 mg/m2 load, 250 mg/m2 IV, q1w)
Number of subjects: 121
Study 25665116 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOSEAL 5 mL
Number of subjects: 157
Study 25665116 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOSEAL 10 mL
Number of subjects: 157
Study 25665116 — intervention group
Group type: COMPARATOR
Intervention: Control group (no FLOSEAL)
Number of subjects: 157
Study 23046438 — intervention group
Group type: EXPERIMENTAL
Intervention: Black currant anthocyanins (BCACs) 50 mg/day
Number of subjects: 33
Study 23046438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 23046438 — intervention group
Group type: EXPERIMENTAL
Intervention: Black currant anthocyanins (BCACs)
Number of subjects: 33
Study 21966075 — intervention group
Group type: EXPERIMENTAL
Intervention: DXP 3 mg
Number of subjects: 221
Study 21966075 — intervention group
Group type: EXPERIMENTAL
Intervention: DXP 6 mg
Number of subjects: 221
Study 21966075 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 221
Study 17888542 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie milkshake preload
Number of subjects: 0
Study 17888542 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie milkshake preload
Number of subjects: 0
Study 17888542 — intervention group
Group type: COMPARATOR
Intervention: No preload
Number of subjects: 0
Study 16702703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16702703 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical actions (e.g., speak positively about treatments, provide encouragement)
Number of subjects: 0
Study 12811019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with standardized ragweed pollen extract tablets
Number of subjects: 110
Study 12811019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with highest dose (3 tablets 3 times a week)
Number of subjects: 110
Study 12811019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 11198487 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive supranuclear palsy (PSP)
Number of subjects: 8
Study 11198487 — intervention group
Group type: COMPARATOR
Intervention: Healthy patients
Number of subjects: 8
Study 11198487 — intervention group
Group type: COMPARATOR
Intervention: Multiple system atrophy (MSA)
Number of subjects: 8
Study 11198487 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (PSP, Healthy, MSA)
Number of subjects: 8
Study 8649658 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mmol/l Ca dialysate
Number of subjects: 45
Study 8649658 — intervention group
Group type: COMPARATOR
Intervention: 1.75 mmol/l Ca dialysate
Number of subjects: 45
Study 1350803 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine at 10 mg/ml
Number of subjects: 10
Study 1350803 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine at 30 mg/ml
Number of subjects: 10
Study 1350803 — intervention group
Group type: EXPERIMENTAL
Intervention: Nociceptive pain
Number of subjects: 10
Study 1350803 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathic pain
Number of subjects: 10
Study 1350803 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood changes
Number of subjects: 10
Study 6209080 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcainide (100 mg/d by mouth, three times daily)
Number of subjects: 20
Study 6209080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30853602 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) at 30% of PImax, three times a week for four weeks
Number of subjects: 22
Study 30311885 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous CABG and CEA
Number of subjects: 323
Study 30311885 — intervention group
Group type: COMPARATOR
Intervention: Staged CABG and CEA
Number of subjects: 323
Study 26661888 — intervention group
Group type: EXPERIMENTAL
Intervention: Karate training
Number of subjects: 68
Study 26661888 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness training
Number of subjects: 68
Study 26661888 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 24722493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (INT)
Number of subjects: 1217
Study 24722493 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CONV)
Number of subjects: 1217
Study 24722493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheiroarthropathy presence
Number of subjects: 1217
Study 24722493 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH functional disability scores
Number of subjects: 1217
Study 22398060 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily mesalazine (1×2 g)
Number of subjects: 0
Study 22398060 — intervention group
Group type: COMPARATOR
Intervention: Twice daily mesalazine (2×1 g)
Number of subjects: 0
Study 19931399 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmedicated BD subjects
Number of subjects: 35
Study 19931399 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated BD subjects
Number of subjects: 35
Study 19931399 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (matched to unmedicated BD subjects)
Number of subjects: 35
Study 19931399 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (matched to medicated BD subjects)
Number of subjects: 35
Study 17081574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention A (small breakfast, snack, and standard lunch)
Number of subjects: 69
Study 17081574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention B (standard breakfast, snack, and small lunch)
Number of subjects: 69
Study 17081574 — intervention group
Group type: COMPARATOR
Intervention: Control (standard breakfast, no snack and standard lunch)
Number of subjects: 69
Study 17081574 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-morning snack (part of both interventions A and B)
Number of subjects: 69
Study 15740828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pentazocine (0.5mg/kg)
Number of subjects: 88
Study 12164994 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive occupational therapy (OT)
Number of subjects: 163
Study 12164994 — intervention group
Group type: COMPARATOR
Intervention: Active control (social activity group)
Number of subjects: 163
Study 12164994 — intervention group
Group type: COMPARATOR
Intervention: Passive control (nontreatment group)
Number of subjects: 163
Study 10207539 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir 800 mg three times a day
Number of subjects: 284
Study 10207539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 600 mg twice a day
Number of subjects: 284
Study 10207539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 400 mg twice a day and saquinavir 400 mg twice a day
Number of subjects: 284
Study 10207539 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir (in antiretroviral drug-naive patients)
Number of subjects: 284
Study 10207539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (in antiretroviral drug-naive patients)
Number of subjects: 284
Study 10207539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir + saquinavir (in antiretroviral drug-naive patients)
Number of subjects: 284
Study 10207539 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir (in drug-experienced patients)
Number of subjects: 284
Study 10207539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (in drug-experienced patients)
Number of subjects: 284
Study 10207539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir + saquinavir (in drug-experienced patients)
Number of subjects: 284
Study 9097805 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival mitomycin C (0.5 mg/ml) applied for 1-, 3-, or 5-minutes
Number of subjects: 78
Study 9097805 — intervention group
Group type: COMPARATOR
Intervention: No mitomycin C (Control)
Number of subjects: 78
Study 2710266 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ranitidine 50 mg
Number of subjects: 6
Study 2710266 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ranitidine 150 mg
Number of subjects: 6
Study 47944 — intervention group
Group type: EXPERIMENTAL
Intervention: C.F. antibodies (IgG)
Number of subjects: 173
Study 47944 — intervention group
Group type: EXPERIMENTAL
Intervention: I.D. technique (IgM and/or low titres of IgG)
Number of subjects: 173
Study 31941483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular HADMSCs injection with LIPUS
Number of subjects: 96
Study 31941483 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular HADMSCs injection with sham LIPUS
Number of subjects: 96
Study 31941483 — intervention group
Group type: COMPARATOR
Intervention: Normal saline with LIPUS
Number of subjects: 96
Study 30224325 — intervention group
Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition
Number of subjects: 1440
Study 30224325 — intervention group
Group type: COMPARATOR
Intervention: Early parenteral nutrition
Number of subjects: 1440
Study 28608756 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 478
Study 28608756 — intervention group
Group type: COMPARATOR
Intervention: Guidelines-based asthma care
Number of subjects: 478
Study 25707331 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 900
Study 25707331 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 900
Study 25707331 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropins
Number of subjects: 900
Study 23881774 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy fiber (SF) biscuits (approximately 100 g/day) for 12 weeks
Number of subjects: 39
Study 23881774 — intervention group
Group type: COMPARATOR
Intervention: Control biscuits for 12 weeks
Number of subjects: 39
Study 21441616 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg daily) for 30 and 90 days
Number of subjects: 59
Study 21441616 — intervention group
Group type: COMPARATOR
Intervention: Phytohemagglutinin-stimulated T lymphocytes
Number of subjects: 59
Study 19624576 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg, maximum 400 mg)
Number of subjects: 66
Study 19624576 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen-codeine (1 mg/kg as codeine, maximum 60 mg)
Number of subjects: 66
Study 17105953 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB 40 mg/kg
Number of subjects: 8
Study 17105953 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB 50 mg/kg
Number of subjects: 8
Study 17105953 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB 60 mg/kg
Number of subjects: 8
Study 17105953 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB 72 mg/kg
Number of subjects: 8
Study 15152747 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin K antagonists (e.g., warfarin) for stroke prevention in AF
Number of subjects: 2300000
Study 12100790 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Assisted Meal Related Insulin Therapy (CAMIT)
Number of subjects: 50
Study 12100790 — intervention group
Group type: COMPARATOR
Intervention: Multiple Subcutaneous Injection (MSI)
Number of subjects: 50
Study 9801184 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term chemoprophylaxis (minimum 14 days and 7 days without the onset of a case)
Number of subjects: 700
Study 9801184 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term chemoprophylaxis (minimum 21 days and 7 days without the onset of a case)
Number of subjects: 700
Study 9166489 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour infusion of paclitaxel (135 mg/m2)
Number of subjects: 164
Study 9166489 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour infusion of paclitaxel (200 mg/m2)
Number of subjects: 164
Study 9166489 — intervention group
Group type: COMPARATOR
Intervention: 3-day divided dose schedule of paclitaxel (200 mg/m2)
Number of subjects: 164
Study 9166489 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day schedule of paclitaxel
Number of subjects: 164
Study 9166489 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of paclitaxel (135 mg/m2 and 200 mg/m2)
Number of subjects: 164
Study 9166489 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/m2 dose of paclitaxel in non-small cell lung cancer
Number of subjects: 164
Study 2515220 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (dexamethasone)
Number of subjects: 126
Study 334211 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg once-daily
Number of subjects: 21
Study 334211 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once-daily
Number of subjects: 21
Study 334211 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg once-daily
Number of subjects: 21
Study 334211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31724239 — intervention group
Group type: EXPERIMENTAL
Intervention: Deproteinized bovine bone mineral (DBBM)
Number of subjects: 100
Study 31724239 — intervention group
Group type: EXPERIMENTAL
Intervention: Deproteinized porcine bone mineral (DPBM)
Number of subjects: 100